

Cover Story
The FDA Oncologic Drugs Advisory Committee Feb. 26 voted down a vascular-targeted photodynamic therapy for early-stage, low-risk prostate cancer and, in a narrow vote, recommended approval for a combination of a VEGF receptor 2 antagonist and an EGFR-targeting tyrosine kinase inhibitor for front-line treatment of EGFR-positive non-small cell lung cancer.
By Alexandria Carolan
In Brief
Clinical Roundup
Drugs & Targets


Trending Stories
- Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight
NCI to remain intact, but its finances are uncertain; FDA is spared big cuts - John Burklow replaced by Seana Cranston as NIH chief of staff
- In the Headlines: What’s in Trump’s draft budget?
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - NCI summarizes changes to the CCSG NOFO
- City of Hope’s BMT program performs 20,000th transplant
49-year history creates 20,000 tomorrows